RNA interference (RNAi) has been widely adopted to repress specific gene expression and is easily achieved by designing small interfering RNAs (siRNAs) with perfect sequence complementarity to the intended target mRNAs. Although siRNAs direct Argonaute (Ago), a core component of the RNA-induced silencing complex (RISC), to recognize and silence target mRNAs, they also inevitably function as microRNAs (miRNAs) and suppress hundreds of off-targets. Such miRNA-like off-target repression is potentially detrimental, resulting in unwanted toxicity and phenotypes. Despite early recognition of the severity of miRNA-like off-target repression, this effect has often been overlooked because of difficulties in recognizing and avoiding off-targets. However, recent advances in genome-wide methods and knowledge of Ago-miRNA target interactions have set the stage for properly evaluating and controlling miRNA-like off-target repression. Here, we describe the intrinsic problems of miRNA-like off-target effects caused by canonical and noncanonical interactions. We particularly focus on various genome-wide approaches and chemical modifications for the evaluation and prevention of off-target repression to facilitate the use of RNAi with secured specificity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11105550 | PMC |
| http://dx.doi.org/10.1007/s00018-017-2656-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence.
Br J Pharmacol
January 2025
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Three types of highly promising small RNA therapeutics, namely, small interfering RNAs (siRNAs), microRNAs (miRNAs) and the RNA subtype of antisense oligonucleotides (ASOs), offer advantages over small-molecule drugs. These small RNAs can target any gene product, opening up new avenues of effective and safe therapeutic approaches for a wide range of diseases. In preclinical research, synthetic small RNAs play an essential role in the investigation of physiological and pathological pathways as silencers of specific genes, facilitating discovery and validation of drug targets in different conditions.
View Article and Find Full Text PDFYB-1 Is a Novel Target for the Inhibition of α-Adrenergic-Induced Hypertrophy.
Int J Mol Sci
December 2023
Institute of Physiology, Justus Liebig University, 35392 Giessen, Germany.
Article Synopsis
- Cardiac hypertrophy, triggered by sympathetic nervous system activation, can lead to heart failure, and the transcription factor YB-1 may play a key role in managing this process.
- In human heart biopsies from patients with ischemic cardiomyopathy, YB-1 expression is found to be downregulated, which correlates with the development of heart failure.
- Research using siRNA techniques on cardiac cells indicates that reducing YB-1 leads to increased hypertrophic growth, while overexpressing YB-1 can inhibit hypertrophic responses under certain stimuli, suggesting that maintaining YB-1 levels is crucial for heart protection.
siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects.
Front Plant Sci
January 2021
Regensburg Center for Biochemistry (RCB), Laboratory for RNA Biology, University of Regensburg, Regensburg, Germany.
Short interfering RNAs (siRNAs) are processed from long double-stranded RNA (dsRNA), and a guide strand is selected and incorporated into the RNA-induced silencing complex (RISC). Within RISC, a member of the Argonaute protein family directly binds the guide strand and the siRNA guides RISC to fully complementary sites on-target RNAs, which are then sequence-specifically cleaved by the Argonaute protein-a process commonly referred to as RNA interference (RNAi). In animals, endogenous microRNAs (miRNAs) function similarly but do not lead to direct cleavage of the target RNA but to translational inhibition followed by exonucleolytic decay.
View Article and Find Full Text PDFsiAbasic: a comprehensive database for potent siRNA-6Ø sequences without off-target effects.
Database (Oxford)
January 2018
Department of Life Sciences, Korea University, Seoul, Korea.
Small interfering RNA (siRNA) is widely used to specifically silence target gene expression, but its microRNA (miRNA)-like function inevitably suppresses hundreds of off-targets. Recently, complete elimination of the off-target repression has been achieved by introducing an abasic nucleotide to the pivot (position 6; siRNA-6Ø), of which impaired base pairing destabilizes transitional nucleation (positions 2-6). However, siRNA-6Ø varied in its conservation of on-target activity (∼80-100%), demanding bioinformatics to discover the principles underlying its on-target efficiency.
View Article and Find Full Text PDFEvaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map.
PLoS Biol
November 2017
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
The application of RNA interference (RNAi) to mammalian cells has provided the means to perform phenotypic screens to determine the functions of genes. Although RNAi has revolutionized loss-of-function genetic experiments, it has been difficult to systematically assess the prevalence and consequences of off-target effects. The Connectivity Map (CMAP) represents an unprecedented resource to study the gene expression consequences of expressing short hairpin RNAs (shRNAs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!